{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:09:28Z","timestamp":1779448168200,"version":"3.53.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.semdp.2026.151010","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:52:30Z","timestamp":1776383550000},"page":"151010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular findings in thyroid tumors: Practical diagnostic, prognostic, and therapeutic insights"],"prefix":"10.1016","volume":"43","author":[{"given":"Lauren","family":"Stark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C.","family":"Dueber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-2474","authenticated-orcid":false,"given":"Derek B.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semdp.2026.151010_bib0001","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.semdp.2026.151010_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006239","article-title":"Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers","volume":"12","author":"Yoo","year":"2016","journal-title":"PLoS Genet"},{"issue":"3","key":"10.1016\/j.semdp.2026.151010_bib0003","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.eprac.2020.09.003","article-title":"Pathologic features associated with molecular subtypes of well-differentiated thyroid cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.semdp.2026.151010_bib0004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13044-025-00231-0","article-title":"Molecular alteration patterns predict tumor behavior in papillary thyroid carcinoma independent of tumor size: insights from an international multicenter retrospective study","volume":"18","author":"Morand","year":"2025","journal-title":"Thyroid Res"},{"issue":"11","key":"10.1016\/j.semdp.2026.151010_bib0005","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1210\/clinem\/dgad220","article-title":"Molecular profiling of 50 734 Bethesda III-VI thyroid nodules by ThyroSeq v3: implications for personalized management","volume":"108","author":"Chiosea","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0006","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamaoncol.2018.4616","article-title":"Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study","volume":"5","author":"Steward","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0007","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.semdp.2026.151010_bib0008","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","article-title":"Consensus Statement: recommendations on actionable biomarker testing for thyroid cancer management","volume":"35","author":"Mete","year":"2024","journal-title":"Endocr Pathol"},{"issue":"7","key":"10.1016\/j.semdp.2026.151010_bib0009","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.semdp.2026.151010_bib0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/thy.2021.0542","article-title":"Clinical application of next-generation sequencing in advanced thyroid cancers","volume":"32","author":"Ma","year":"2022","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0011","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jasc.2021.07.002","article-title":"Performance of Afirma gene sequencing classifier versus gene expression classifier in thyroid nodules with indeterminate cytology","volume":"11","author":"Yang","year":"2022","journal-title":"J Am Soc Cytopathol"},{"issue":"1","key":"10.1016\/j.semdp.2026.151010_bib0012","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.surg.2023.07.042","article-title":"Clinical utility of a microRNA classifier in cytologically indeterminate thyroid nodules with RAS mutations: a multi-institutional study","volume":"175","author":"Tumati","year":"2024","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.07.002","article-title":"Integrated genomic analysis of h\u00fcrthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes","volume":"34","author":"Ganly","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0014","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/his.14550","article-title":"Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases","volume":"80","author":"Xu","year":"2022","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.semdp.2026.151010_bib0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12022-016-9445-4","article-title":"Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma","volume":"27","author":"Xu","year":"2016","journal-title":"Endocr Pathol"},{"issue":"13","key":"10.1016\/j.semdp.2026.151010_bib0016","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clinical Cancer Res"},{"issue":"4","key":"10.1016\/j.semdp.2026.151010_bib0017","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.semdp.2026.151010_bib0018","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"IScience"},{"issue":"7","key":"10.1016\/j.semdp.2026.151010_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/genes14071314","article-title":"Update on molecular diagnostics in thyroid pathology: a review","volume":"14","author":"Alzumaili","year":"2023","journal-title":"Genes (Basel)"},{"issue":"5","key":"10.1016\/j.semdp.2026.151010_bib0020","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.21037\/gs-20-356","article-title":"Genetic differences in follicular thyroid carcinoma between Asian and western countries: a systematic review","volume":"9","author":"Odate","year":"2020","journal-title":"Gland Surg"},{"issue":"8","key":"10.1016\/j.semdp.2026.151010_bib0021","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40618-015-0311-x","article-title":"Analysis of RAS mutation and PAX8\/ppar\u03b3 rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings","volume":"38","author":"Jeong","year":"2015","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0022","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12105-019-01124-z","article-title":"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): an update","volume":"14","author":"Xu","year":"2020","journal-title":"Head Neck Pathol"},{"issue":"7","key":"10.1016\/j.semdp.2026.151010_bib0023","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1210\/jc.2018-00277","article-title":"Comprehensive genetic analysis of follicular thyroid carcinoma predicts prognosis independent of histology","volume":"103","author":"Nicolson","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.semdp.2026.151010_bib0024","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-06-1125","article-title":"Genetic alterations and their relationship in the phosphatidylinositol 3-kinase\/akt pathway in thyroid cancer","volume":"13","author":"Hou","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.semdp.2026.151010_bib0025","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1002\/hed.27950","article-title":"The prevalence and prognostic implications of BRAF K601E mutations in thyroid neoplasms: a systematic review and meta-analysis","volume":"46","author":"Webster","year":"2024","journal-title":"Head Neck"},{"issue":"8","key":"10.1016\/j.semdp.2026.151010_bib0026","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1089\/thy.2019.0415","article-title":"Thyroid cancer incidence trends in the United States: association with changes in professional guideline recommendations","volume":"30","author":"Pereira","year":"2020","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.semdp.2026.151010_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2024.104570","article-title":"Decoding RAS mutations in thyroid cancer: a meta-analysis unveils specific links to distant metastasis and increased mortality","volume":"46","author":"Riccio","year":"2025","journal-title":"Am J Otolaryngol"},{"issue":"5","key":"10.1016\/j.semdp.2026.151010_bib0028","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.21037\/gs-20-430","article-title":"Prevalence of BRAF(V600E) mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review","volume":"9","author":"Rashid","year":"2020","journal-title":"Gland Surg"},{"issue":"1","key":"10.1016\/j.semdp.2026.151010_bib0029","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12022-021-09666-1","article-title":"Molecular pathology of non-familial follicular epithelial-derived thyroid cancer in adults: from RAS\/BRAF-like tumor designations to Molecular risk stratification","volume":"32","author":"Soares","year":"2021","journal-title":"Endocr Pathol"},{"issue":"26","key":"10.1016\/j.semdp.2026.151010_bib0030","doi-asserted-by":"crossref","first-page":"40792","DOI":"10.18632\/oncotarget.8215","article-title":"Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.semdp.2026.151010_bib0031","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1089\/thy.2013.0573","article-title":"Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile","volume":"24","author":"Lubitz","year":"2014","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.semdp.2026.151010_bib0032","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/his.14374","article-title":"Genomic profile of columnar cell variant of papillary thyroid carcinoma","volume":"79","author":"Janovitz","year":"2021","journal-title":"Histopathology"},{"issue":"12","key":"10.1016\/j.semdp.2026.151010_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100329","article-title":"A detailed histologic and molecular assessment of the diffuse sclerosing variant of papillary thyroid carcinoma","volume":"36","author":"Chou","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.semdp.2026.151010_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1346476","article-title":"Systemic treatments for radioiodine-refractory thyroid cancers","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.semdp.2026.151010_bib0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid Cancer: a review","volume":"331","author":"Boucai","year":"2024","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.06.013","article-title":"Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in h\u00fcrthle cell carcinoma","volume":"34","author":"Gopal","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.semdp.2026.151010_bib0037","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/dc.20750","article-title":"Fine-needle aspiration cytology of h\u00fcrthle cell carcinoma of the thyroid","volume":"36","author":"Wu","year":"2008","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.semdp.2026.151010_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.549882","article-title":"Clinical, pathological, and molecular characteristics correlating to the occurrence of radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis","volume":"10","author":"Luo","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0039","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12022-015-9367-6","article-title":"Poorly differentiated oncocytic (h\u00fcrthle cell) follicular carcinoma: an institutional experience","volume":"26","author":"Bai","year":"2015","journal-title":"Endocr Pathol"},{"issue":"7","key":"10.1016\/j.semdp.2026.151010_bib0040","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1089\/thy.2011.0407","article-title":"Histological patterns of locoregional recurrence in h\u00fcrthle cell carcinoma of the thyroid gland","volume":"22","author":"Bishop","year":"2012","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.semdp.2026.151010_bib0041","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1210\/jc.2013-3842","article-title":"Outcomes in patients with poorly differentiated thyroid carcinoma","volume":"99","author":"Ibrahimpasic","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.semdp.2026.151010_bib0042","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa655","article-title":"The oncocytic variant of poorly differentiated thyroid carcinoma shows a specific immune-related gene expression profile","volume":"105","author":"Metovic","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.semdp.2026.151010_bib0043","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/cncy.22375","article-title":"H\u00fcrthle cell lesions of the thyroid: progress made and challenges remaining","volume":"129","author":"Wong","year":"2021","journal-title":"Cancer Cytopathol"},{"issue":"21","key":"10.1016\/j.semdp.2026.151010_bib0044","doi-asserted-by":"crossref","first-page":"9001","DOI":"10.1073\/pnas.0703056104","article-title":"Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors","volume":"104","author":"Gasparre","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.semdp.2026.151010_bib0045","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1053\/hupa.2000.8444","article-title":"Interphase cytogenetics in oncocytic adenomas and carcinomas of the thyroid gland","volume":"31","author":"Mazzucchelli","year":"2000","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.semdp.2026.151010_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038287","article-title":"Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma","volume":"7","author":"Corver","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.semdp.2026.151010_bib0047","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/00000478-200107000-00009","article-title":"Analysis of hurthle cell neoplasms of the thyroid by interphase fluorescence in situ hybridization","volume":"25","author":"Erickson","year":"2001","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.semdp.2026.151010_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32040224","article-title":"Folliculin (FLCN) in thyroid tumors: incidence, significance, and role as a driver gene and secondary alteration","volume":"32","author":"Hassan","year":"2025","journal-title":"Curr Oncol"},{"key":"10.1016\/j.semdp.2026.151010_bib0049","doi-asserted-by":"crossref","first-page":"159","DOI":"10.12688\/f1000research.4205.1","article-title":"Case Report: expanding the tumour spectrum associated with the Birt-Hogg-Dub\u00e9 cancer susceptibility syndrome","volume":"3","author":"Benusiglio","year":"2014","journal-title":"F1000Res"},{"issue":"1","key":"10.1016\/j.semdp.2026.151010_bib0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ccr3.3454","article-title":"Metastatic follicular thyroid cancer in a patient with Birt-Hogg-Dub\u00e9 syndrome","volume":"9","author":"Bongetti","year":"2021","journal-title":"Clin Case Rep"},{"issue":"22","key":"10.1016\/j.semdp.2026.151010_bib0051","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003695","article-title":"Case report of Birt-Hogg-Dub\u00e9 Syndrome: germline mutations of FLCN detected in patients with renal cancer and thyroid cancer","volume":"95","author":"Dong","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.semdp.2026.151010_bib0052","article-title":"Oncocytic thyroid tumours with pathogenic FLCN mutations mimic oncocytic papillary thyroid carcinoma on fine-needle aspiration","author":"Ashraf","year":"2025","journal-title":"Cytopathology"},{"issue":"6","key":"10.1016\/j.semdp.2026.151010_bib0053","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.semdp.2026.151010_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115193","article-title":"Alectinib for the treatment of papillary thyroid carcinoma harbouring <em>STRN \u2013 ALK<\/em>fusion","volume":"216","author":"Buriolla","year":"2025","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.semdp.2026.151010_bib0055","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1089\/thy.2020.0589","article-title":"Clinicopathologic characteristics of thyroid nodules positive for the THADA-IGF2BP3 fusion on preoperative molecular analysis","volume":"31","author":"Morariu","year":"2021","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.semdp.2026.151010_bib0056","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1614265114","article-title":"THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer","volume":"114","author":"Panebianco","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.semdp.2026.151010_bib0057","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051575","article-title":"Characteristics of PTEN mutation in thyroid tumours: a retrospective chart review","volume":"15","author":"Bandargal","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semdp.2026.151010_bib0058","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2018.04.018","article-title":"Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors","volume":"81","author":"Jung","year":"2018","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.semdp.2026.151010_bib0059","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/cncy.22811","article-title":"Thyroid nodules with DICER1 mutation or PTEN alteration: a comparative cytologic, clinical, and molecular study of 117 FNA cases","volume":"132","author":"Jitpasutham","year":"2024","journal-title":"Cancer Cytopathol"},{"issue":"4","key":"10.1016\/j.semdp.2026.151010_bib0060","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgab025","article-title":"Prevalence and spectrum of DICER1 mutations in adult-onset thyroid nodules with indeterminate cytology","volume":"106","author":"Chong","year":"2021","journal-title":"J Clinic Endocrinol Metabol"},{"issue":"8","key":"10.1016\/j.semdp.2026.151010_bib0061","doi-asserted-by":"crossref","DOI":"10.1002\/cncy.70029","article-title":"DICER1 mutations in Bethesda category II, III, and IV thyroid nodules: a mutually exclusive relationship with BRAFV600E mutation","volume":"133","author":"Wang","year":"2025","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"10.1016\/j.semdp.2026.151010_bib0062","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00428-024-03802-y","article-title":"Atrophic changes in thyroid tumors are strong indicators of underlying DICER1 mutations: a bi-institutional genotype-phenotype correlation study","volume":"485","author":"Condello","year":"2024","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0063","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/PAP.0000000000000364","article-title":"From malignant thyroid teratoma to thyroblastoma: evolution of a newly-recognized DICER1 -associated malignancy","volume":"30","author":"Rooper","year":"2023","journal-title":"Adv Anat Pathol"},{"issue":"6","key":"10.1016\/j.semdp.2026.151010_bib0064","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/PAS.0000000000001430","article-title":"Recurrent DICER1 hotspot mutations in malignant thyroid gland teratomas: molecular characterization and proposal for a separate classification","volume":"44","author":"Rooper","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"20","key":"10.1016\/j.semdp.2026.151010_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205184","article-title":"Molecular signature expands the landscape of driver negative thyroid cancers","volume":"13","author":"Bim","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.semdp.2026.151010_bib0066","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41379-018-0070-2","article-title":"Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT\/\u03b2-catenin pathway","volume":"31","author":"Cameselle-Teijeiro","year":"2018","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0067","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/thy.2018.0791","article-title":"GLIS rearrangement is a genomic hallmark of hyalinizing trabecular tumor of the thyroid gland","volume":"29","author":"Nikiforova","year":"2019","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.semdp.2026.151010_bib0068","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1038\/s41379-019-0313-x","article-title":"PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid","volume":"32","author":"Marchi\u00f2","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.semdp.2026.151010_bib0069","doi-asserted-by":"crossref","first-page":"19","DOI":"10.25259\/Cytojournal_34_2023","article-title":"Diagnostic clues for hyalinizing trabecular tumor on fine needle aspiration cytology","volume":"20","author":"Nielsen","year":"2023","journal-title":"Cytojournal"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0070","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12022-021-09700-2","article-title":"Thyroid carcinoma with NSD3::NUTM1 fusion: a case with thyrocyte differentiation and colloid production","volume":"33","author":"Allison","year":"2022","journal-title":"Endocr Pathol"},{"issue":"12","key":"10.1016\/j.semdp.2026.151010_bib0071","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/PAS.0000000000001967","article-title":"NUTM1 -rearranged carcinoma of the thyroid: a distinct subset of NUT carcinoma characterized by frequent NSD3 - NUTM1 fusions","volume":"46","author":"Barletta","year":"2022","journal-title":"Am J Surg Pathol"},{"issue":"21","key":"10.1016\/j.semdp.2026.151010_bib0072","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1702086114","article-title":"Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma","volume":"114","author":"Alekseyenko","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.semdp.2026.151010_bib0073","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1101\/gad.267583.115","article-title":"The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains","volume":"29","author":"Alekseyenko","year":"2015","journal-title":"Genes Dev"},{"issue":"9","key":"10.1016\/j.semdp.2026.151010_bib0074","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.semdp.2026.151010_bib0075","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.semdp.2026.151010_bib0076","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer","volume":"99","author":"Liu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.semdp.2026.151010_bib0077","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12022-016-9445-4","article-title":"Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma","volume":"27","author":"Xu","year":"2016","journal-title":"Endocr Pathol"},{"issue":"6","key":"10.1016\/j.semdp.2026.151010_bib0078","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1089\/thy.2020.0668","article-title":"Papillary thyroid carcinoma with high-grade features versus poorly differentiated thyroid carcinoma: an analysis of clinicopathologic and molecular features and outcome","volume":"31","author":"Wong","year":"2021","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.semdp.2026.151010_bib0079","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/PAS.0b013e3180309e6a","article-title":"Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach","volume":"31","author":"Volante","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.semdp.2026.151010_bib0080","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.21873\/anticanres.14915","article-title":"Prognostic factors and survival score for patients with anaplastic thyroid carcinoma: a retrospective study from a regional registry","volume":"41","author":"Marchand-Crety","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.semdp.2026.151010_bib0081","unstructured":"g."},{"issue":"3","key":"10.1016\/j.semdp.2026.151010_bib0082","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00428-019-02708-4","article-title":"PAX8 expression in anaplastic thyroid carcinoma is less than those reported in early studies: a multi-institutional study of 182 cases using the monoclonal antibody MRQ-50","volume":"476","author":"Lai","year":"2020","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.semdp.2026.151010_bib0083","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12022-021-09665-2","article-title":"Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know?","volume":"32","author":"Volante","year":"2021","journal-title":"Endocr Pathol"},{"issue":"3","key":"10.1016\/j.semdp.2026.151010_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113826","article-title":"The genomic and evolutionary landscapes of anaplastic thyroid carcinoma","volume":"43","author":"Zeng","year":"2024","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.semdp.2026.151010_bib0085","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1210\/jc.2016-3756","article-title":"Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study","volume":"102","author":"Chintakuntlawar","year":"2017","journal-title":"J Clinic Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.semdp.2026.151010_bib0086","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.path.2024.04.002","article-title":"Precision medicine in cytopathology","volume":"17","author":"Piecoro","year":"2024","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.semdp.2026.151010_bib0087","article-title":"Molecular Tumor Board-assisted care in an advanced cancer population: results of a phase II clinical trial","volume":"6","author":"Miller","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.semdp.2026.151010_bib0088","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"9940","key":"10.1016\/j.semdp.2026.151010_bib0089","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.semdp.2026.151010_bib0090","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.semdp.2026.151010_bib0091","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of response with Selpercatinib in patients with RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.semdp.2026.151010_bib0092","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diab Endocrinol"},{"issue":"1","key":"10.1016\/j.semdp.2026.151010_bib0093","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/thy.2023.0363","article-title":"Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study","volume":"34","author":"Subbiah","year":"2024","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.semdp.2026.151010_bib0094","first-page":"1184","article-title":"Dabrafenib versus Dabrafenib + Trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.semdp.2026.151010_bib0095","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semdp.2026.151010_bib0096","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-20-2771","article-title":"FDA approval summary: entrectinib for the treatment of NTRK gene fusion Solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.semdp.2026.151010_bib0097","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.semdp.2026.151010_bib0098","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/cen.15291","article-title":"The efficacy and safety of Pembrolizumab in anaplastic thyroid carcinoma: a systematic review and meta-analysis","volume":"103","author":"Xu","year":"2025","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257026000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257026000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:51:30Z","timestamp":1779447090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257026000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0740257026000304"],"URL":"https:\/\/doi.org\/10.1016\/j.semdp.2026.151010","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular findings in thyroid tumors: Practical diagnostic, prognostic, and therapeutic insights","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semdp.2026.151010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151010"}}